Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Cyclophosphamide 118 pembrolizumab 104 Specimen Handling 104 Magnetic Resonance Spectroscopy 94 fludarabine 92 Biopsy 77 Injections 53 Nivolumab 43 Bevacizumab 41 Fluorouracil 38 venetoclax 37 Cisplatin 36 Paclitaxel 35 Carboplatin 35 Cetuximab 34 Radiotherapy 31 Oxaliplatin 30 fludarabine phosphate 29 Leucovorin 28 Gemcitabine 28 Drug Therapy 25 Ipilimumab 23 Immunotherapy, Adoptive 23 Azacitidine 23 Radiation 21 Irinotecan 21 Temozolomide 20 Doxorubicin 20 tislelizumab 19 atezolizumab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recruiting × Maximum Tolerated Dose × Clear all

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡